Scholarly Research Exchange

Scholarly Research Exchange / 2009 / Article

Research Article | Open Access

Volume 2009 |Article ID 834879 | 7 pages |

Co-administration of Fluoxetine Alters the Steady State Pharmacokinetics of Fluconazole after Multiple Oral Administration in Dogs

Received30 Jan 2009
Revised15 May 2009
Accepted23 Jun 2009
Published28 Jul 2009


Objectives. Fluconazole is an antifungal agent which has become the mainstay treatment of opportunistic fungal infections in immuno-compromized patients. Fluoxetine is a selective serotonine reuptake inhibitor used in the treatment of psychiatric disorders. In the current study we investigated the effect of chronic administration of fluoxetine on the steady state pharmacokinetics parameters of fluconazole. Methods. The pharmacokinetics of Fluconazole, following 10 mg/kg single and multiple oral dosing for 10 days, was determined in dogs. Subsequently, the effect of 2 mg/kg fluoxetine given for 10 days, on the pharmacokinetics of Fluconazole was investigated. Results. The co-administration resulted in significant reduction of 40.1% and 35.6% in AUC 0-, and Cmax, respectively compared to fluconazole alone. A significant alteration of Vss/F was also seen as it increased from 0.242 ± 0.04 to 0.654 ± 0.17 l/kg (P<.01). Accordingly, a significant reduction in Kel from 0.048 ± 0.01 hr-1 to 0.031 ± 0.01 was detected (P<.01). Conclusion. fluoxetine reduced plasma concentration of fluconazole. The mechanism of the interaction is probably the inhibition of OATP or other transporters in the intestinal wall. This interaction may have significant clinical importance because reduction in fluconazole may lead to treatment failure of fungal infection.


  1. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich, “Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians,” Journal of Pharmacology and Experimental Therapeutics, vol. 270, no. 1, pp. 414–423, 1994. View at: Google Scholar
  2. M. T. Pasko, S. C. Piscitelli, and A. D. Van Slooten, “Fluconazole: a new triazole antifungal agent,” DICP, vol. 24, no. 9, pp. 860–867, 1990. View at: Google Scholar
  3. R. L. Slaughter and D. J. Edwards, “Recent advances: the Cytochrome P450 enzymes,” Annals of Pharmacotherapy, vol. 29, no. 6, pp. 619–624, 1995. View at: Google Scholar
  4. K. Richardson, “The discovery and profile of fluconazole,” Journal of Chemotherapy, vol. 2, no. 1, pp. 51–54, 1990. View at: Google Scholar
  5. P. Benfield, R. C. Heel, and S. P. Lewis, “Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness,” Drugs, vol. 32, no. 6, pp. 481–508, 1986. View at: Google Scholar
  6. S. H. Preskorn, R. Shah, M. Neff, A. L. Golbeck, and J. Choi, “The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline,” Journal of Psychiatric Practice, vol. 13, no. 1, pp. 5–12, 2007. View at: Publisher Site | Google Scholar
  7. R. M. Lane, “Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors,” International Clinical Psychopharmacology, vol. 12, no. 2, p. 126, 1997. View at: Google Scholar
  8. J. F. Wernicke, “Safety and side effect profile of fluoxetine,” Expert Opinion on Drug Safety, vol. 3, no. 5, pp. 495–504, 2004. View at: Publisher Site | Google Scholar
  9. J. Amchin, L. Ereshefsky, W. Zarycranski, K. Taylor, D. Albano, and P. M. Klockowski, “Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe,” Journal of Clinical Pharmacology, vol. 41, no. 4, pp. 443–451, 2001. View at: Publisher Site | Google Scholar
  10. S. M. Grant and S. P. Clissold, “Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses,” Drugs, vol. 39, no. 6, pp. 877–916, 1990. View at: Google Scholar
  11. P. O. Gubbins, S. A. McConnell, and S. R. Penzak, “Antifungal Agents,” in Drug Interactions in Infectious Diseases, S. C. Piscitelli and K. A. Rodvold, Eds., Humana Press, Totowa, NJ, USA, 2001. View at: Google Scholar
  12. L. L. Von Moltke, D. J. Greenblatt, J. Schmider et al., “Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents,” Journal of Clinical Pharmacology, vol. 36, no. 9, pp. 783–791, 1996. View at: Google Scholar
  13. T. A. Ketter, D. A. Flockhart, R. M. Post et al., “The emerging role of cytochrome P450 3A in psychopharmacology,” Journal of Clinical Psychopharmacology, vol. 15, no. 6, pp. 387–398, 1995. View at: Publisher Site | Google Scholar
  14. Solvay's Luvox, “Contraindication against co-administration with J&J's Hismanal, MMD's Seldane prompts FDA review of other SSRI labelling,” FDC Reports, The Pink Sheet, 1995. View at: Google Scholar
  15. R. J. Marchiando, M. D. Cook, and S. G. Jue, “Probable terfenadine-fluoxetine-associated cardiac toxicity,” Annals of Pharmacotherapy, vol. 29, no. 9, pp. 937–938, 1995. View at: Google Scholar
  16. M. J. Cupp and T. S. Tract, “Cytochrome P450: new nomenclature and clinical implications,” American Family Physician, vol. 57, no. 1, pp. 107–116, 1998. View at: Google Scholar
  17. D. Gossen, J. M. de Suray, F. Vandenhende, C. Onkelinx, and D. Gangji, “Influence of fluoxetine on olanzapine pharmacokinetics,” AAPS PharmSci, vol. 4, no. 2, p. E11, 2002. View at: Google Scholar
  18. M. J. Humphrey, S. Jevons, and M. H. Tarbit, “Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans,” Antimicrobial Agents and Chemotherapy, vol. 28, no. 5, pp. 648–653, 1985. View at: Google Scholar
  19. N. K. Wadhwa, T. J. Schroeder, E. O'Flaherty, A. J. Pesce, S. A. Myre, and M. R. First, “The effect of oral metoclopramide on the absorption of cyclosporine,” Transplantation, vol. 43, no. 2, pp. 211–213, 1987. View at: Google Scholar
  20. D. Lange, J. H. Pavao, J. Wu, and M. Klausner, “Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers,” Journal of Clinical Pharmacology, vol. 37, no. 6, pp. 535–540, 1997. View at: Google Scholar
  21. S. Jaruratanasirikul and S. Sriwiriyajan, “Effect of omeprazole on the pharmacokinetics of itraconazole,” European Journal of Clinical Pharmacology, vol. 54, no. 2, pp. 159–161, 1998. View at: Publisher Site | Google Scholar
  22. Y. Kanda, M. Kami, T. Matsuyama et al., “Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole,” Hematological Oncology, vol. 16, no. 1, pp. 33–37, 1998. View at: Publisher Site | Google Scholar
  23. A. Johnston, “The pharmacokinetics of voriconazole,” British Journal of Clinical Pharmacology, vol. 56, p. 1, 2003. View at: Google Scholar
  24. R. A. Blum, D. T. D'Andrea, B. M. Florentino et al., “Increased gastric pH and the bioavailability of fluconazole and ketoconazole,” Annals of Internal Medicine, vol. 114, no. 9, pp. 755–757, 1991. View at: Google Scholar
  25. G. K. Dresser, D. G. Bailey, B. F. Leake et al., “Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine,” Clinical Pharmacology and Therapeutics, vol. 71, no. 1, pp. 11–20, 2002. View at: Publisher Site | Google Scholar
  26. A. V. Kamath, M. Yao, Y. Zhang, and S. Chong, “Effect of fruit juices on the oral bioavailability of fexofenadine in rats,” Journal of Pharmaceutical Sciences, vol. 94, no. 2, pp. 233–239, 2005. View at: Publisher Site | Google Scholar
  27. S. D. Hall, K. E. Thummel, P. B. Watkins et al., “Molecular and physical mechanisms of first-pass extraction,” Drug Metabolism and Disposition, vol. 27, no. 2, pp. 161–166, 1999. View at: Google Scholar
  28. E.-J. Wang, K. Lew, C. N. Casciano, R. P. Clement, and W. W. Johnson, “Interaction of common azole antifungals with P glycoprotein,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 1, pp. 160–165, 2002. View at: Publisher Site | Google Scholar
  29. C. M. Pariante, R. B. Kim, A. Makoff, and R. W. Kerwin, “Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters,” British Journal of Pharmacology, vol. 139, no. 6, pp. 1111–1118, 2003. View at: Publisher Site | Google Scholar

Copyright © 2009 Iman Y. Zaghloul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

235 Views | 0 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.